Abstract 472P
Background
Radiological part-solid nodules (PSNs) containing both solid and ground-glass opacity (GGO) component has lower incidence of nodal metastasis and better prognosis than radiological solid nodules. Previous studies demonstrated that risk of recurrence in GGO-predominant PSNs (0< consolidation-to-tumor ratio ≤0.5) was negligible, while recurrence was not rare in solid- predominant PSNs (0.5< consolidation-to-tumor ratio <1). However, the detailed recurrence patterns and the role of adjuvant therapy after recurrence remained unclear in solid-predominant PSNs.
Methods
Patients with cN0 solid-predominant PSNs (0.5< consolidation-to-tumor ratio <1) undergoing surgery from 2008 to 2015 were collected. The exclusion criteria were as follows: (a) adenocarcinoma in situ or minimally invasive adenocarcinoma, (b) history of other malignancy, (c) multiple primary lesions, and (d) positive resection margin. Median follow-up time was 77.0 months. The initial recurrence site and adjuvant treatment data were collected.
Results
This study included 443 solid-predominant PSNs. Postoperative recurrence was diagnosed in 88 patients (19.9%), including 38 (8.6%) distant, 26 (5.9%) locoregional, and 24 (5.4%) combined recurrences. Lymph node metastasis (P=0.011), lymphovascular invasion (P=0.001), and larger solid component size (P=0.007) were independent predictors of postoperative recurrence. Multivariate Cox regression identified older age (P=0.014, HR=1.044) and early recurrence (P<0.001, HR=4.046) as independent predictors of decreased survival in patients who experienced recurrence. EGFR mutation and ALK rearrangement were identified in 44 (50.0%) and 3 (3.4%) patients who experienced recurrence, respectively. Tyrosine kinase inhibitors demonstrated significant advantages over chemotherapy in patients who experienced recurrence. (median overall survival: 75 vs. 52 months, P=0.004).
Conclusions
Radiological solid-predominant PSNs comprise a heterogeneous population. Active follow-up and effective adjuvant treatment is warranted in patients with risk factors of recurrence. Patients with driver mutations can greatly benefit from targeted therapy if recurrence occurs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract